doi.org/10.1016/j.esmoop.2022.100591
Other

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

..., Andrea Casadei‐Gardini
40
ESMO Open
Volume: 7, Issue: 6, Pages: 100591 - 100591
Published: Oct 6, 2022
Paper Fields
Paper Details
Title
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
DOI
doi.org/10.1016/j.esmoop.2022.100591
Published Date
Oct 6, 2022
Journal
ESMO Open
Volume
7
Issue
6
Pages
100591 - 100591
© 2026 Pluto Labs All rights reserved.